An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs

Bibliography

• O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 2009;15(11):4806-14
   PubMedGoogle Scholar
• Watanabe A, Taniguchi M, Sasaki S. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. Anticancer Drugs 2003;14(10):801-7
   PubMedGoogle Scholar
• Fuse N, Doi T, Ohtsu A, Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. Int J Clin Oncol 2008;13(2):144-9
   PubMed Web of Science ®Google Scholar
• Yukawa N, Yamamoto Y, Akaike M, Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer. Gan To Kagaku Ryoho 2010;37(7):1291-5
   PubMedGoogle Scholar
• Arnold FL, Kusama M, Ono S. Exploring differences in drug doses between Japan and Western countries. Clin Pharmacol Ther 2010;87(5):714-20
   PubMedGoogle Scholar
• Gandara DR, Kawaguchi T, Crowley J, Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27(21):3540-6
   PubMed Web of Science ®Google Scholar
• Millward MJ, Boyer MJ, Lehnert M, Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003;14(3):449-54
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Chansky K, Shibata T, Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer 1: Final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer 2010;116(24):5710-15
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Natale R, Crowley J, Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27(15):2530-5
   PubMed Web of Science ®Google Scholar
• Sekine I, Yamamoto N, Nishio K, Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99(11):1757-62
   PubMed Web of Science ®Google Scholar
• Gridelli C, De Marinis F, Di Maio M, Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer 2011;71(3):249-57
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366(9496):1527-37
   PubMed Web of Science ®Google Scholar
• Liu W, Innocenti F, Chen P, Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003;9(3):1009-12
   PubMed Web of Science ®Google Scholar
• Rudin CM, Liu W, Desai A, Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008;26(7):1119-27
   PubMed Web of Science ®Google Scholar
• Ganjoo KN and Wakelee H. Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics 2007;1(4):335-46
   PubMedGoogle Scholar
• Kubota K, Nishiwaki Y, Tamura T, Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008;3(12):1439-45
   PubMed Web of Science ®Google Scholar
• Beith JM, Goh BC, Yeo W, Inter-ethnic differences in the myelotoxicity of adriamycin/cyclophosphamide (AC) for adjuvant breast cancer. Proc Am Soc Clin Oncol 2002;21:252
   Google Scholar
• Ma B, Yeo W, Hui P, Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer – a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 2002;62(2):185-9
   PubMed Web of Science ®Google Scholar
• Moy B, Tu D, Pater JL, Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol 2006;17(11):1637-43
   PubMed Web of Science ®Google Scholar
• McCollum AD, Catalano PJ, Haller DG, Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 2002;94(15):1160-7
   PubMed Web of Science ®Google Scholar
• Sanoff HK, Sargent DJ, Green EM, Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol 2009;27(25):4109-15
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, McLeod H. Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Trans Am Clin Climatol Assoc 2010;121:21-32; discussion 32-3
   PubMedGoogle Scholar
• Plaxe SC, Brooks SE, Tian C, Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies. Am J Obstet Gynecol 2008;199(5):539; e1-6
   PubMedGoogle Scholar
• Farley JH, Tian C, Rose GS, Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer 2009;115(18):4210-17
   PubMed Web of Science ®Google Scholar
• Farley JH, Tian C, Rose GS, Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study. Cancer 2010;116(2):355-61
   PubMed Web of Science ®Google Scholar
• Phan VH, Moore MM, McLachlan AJ, Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol 2009;5(3):243-57
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352(21):2211-21
   PubMed Web of Science ®Google Scholar
• Chen C, Lu RB, Chen YC, Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism. Am J Hum Genet 1999;65(3):795-807
   PubMed Web of Science ®Google Scholar
• Duranceaux N, Shuckit MA, Luczak ME, Ethnic differences in level of response to alcohol between Chinese Americans and Korean Americans. J Stud Alcohol Drugs 2008;69:227-34
   PubMed Web of Science ®Google Scholar
• Ball SE, Scatina J, Kao J, Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999;66(3):288-94
   PubMed Web of Science ®Google Scholar
• Goh B, Soo RA, Zhang LJ, Inter-ethnic variability of S-1 pharmacokinetics (PK) and correlation with CYP2A6 phenotyping. ASCO General Meeting, American Society of Clinical Oncology, Chicago; 2008
   Google Scholar
• Available from: http://www.pharmgkb.org
   Google Scholar
• Available from: www.imm.ki.se/CYPalleles
   Google Scholar
• van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009;35(8):692-706
   PubMed Web of Science ®Google Scholar
• van Erp NP, Eechoute K, van der Veldt AA, Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009;27(26):4406-12
   PubMed Web of Science ®Google Scholar
• Li J, Zhao M, He P, Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007;13(12):3731-7
   PubMed Web of Science ®Google Scholar
• Chowbay B, Zhou S, Lee EJ. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 2005;37(2):327-78
   PubMed Web of Science ®Google Scholar
• Robert J, Morvan VL, Smith D, Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005;54(3):171-96
   PubMed Web of Science ®Google Scholar
• Kaida Y, Inui N, Suda T, The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. Clin Pharmacol Ther 2008;83(4):589-94
   PubMed Web of Science ®Google Scholar
• Nakajima M, Fukami T, Yamanaka H, Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006;80(3):282-97
   PubMed Web of Science ®Google Scholar
• Jinno H, Tanaka-Kagawa T, Ohno A, Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 2003;31(4):398-403
   PubMed Web of Science ®Google Scholar
• Hofmann MH, Blievernicht JK, Klein K, Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008;325(1):284-92
   PubMed Web of Science ®Google Scholar
• Klein K, Lang T, Saussele T, Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005;15(12):861-73
   PubMed Web of Science ®Google Scholar
• Lang T, Klein K, Richter T, Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 2004;311(1):34-43
   PubMed Web of Science ®Google Scholar
• Rotger M, Tegude H, Colombo S, Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007;81(4):557-66
   PubMed Web of Science ®Google Scholar
• Xie H, Griskevicius L, Stahle L, Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci 2006;27(1):54-61
   PubMed Web of Science ®Google Scholar
• Rocha V, Porcher R, Fernandes JF, Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 2009;23(3):545-56
   PubMed Web of Science ®Google Scholar
• Bray J, Sludden J, Griffin MJ, Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010;102(6):1003-9
   PubMed Web of Science ®Google Scholar
• Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 2009;10(9):1489-510
   PubMed Web of Science ®Google Scholar
• Hanioka N, Matsumoto K, Saito Y, Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel. Basic Clin Pharmacol Toxicol 2010;107(1):565-9
   PubMed Web of Science ®Google Scholar
• Marsh S, Paul J, King CR, Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007;25(29):4528-35
   PubMed Web of Science ®Google Scholar
• Marsh S, Somlo G, Li X, Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 2007;7(5):362-5
   PubMed Web of Science ®Google Scholar
• Henningsson A, Marsh S, Loos WJ, Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005;11(22):8097-104
   PubMed Web of Science ®Google Scholar
• Bergmann TK, Brasch-Andersen C, Green H, Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2010;6:6
   Google Scholar
• Leskela S, Jara C, Leandro-Garcia LJ, Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 2010;9:9
   Google Scholar
• Sarasquete ME, Garcia-Sanz R, Marin L, Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008;112(7):2709-12
   PubMed Web of Science ®Google Scholar
• van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 2008;11(3):77-98
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44(9):879-94
   PubMed Web of Science ®Google Scholar
• Givens CB, Bullock LN, Franks AS. Safety of concomitant tamoxifen and warfarin. Ann Pharmacother 2009;43(11):1867-71
   PubMed Web of Science ®Google Scholar
• Van Booven D, Marsh S, McLeod H, Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 2010;20(4):277-81
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Martinez C, Ladero JM, Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10(1):29-40
   PubMed Web of Science ®Google Scholar
• Ekhart C, Doodeman VD, Rodenhuis S, Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008;18(6):515-23
   PubMed Web of Science ®Google Scholar
• Schroth W, Antoniadou L, Fritz P, Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25(33):5187-93
   PubMed Web of Science ®Google Scholar
• Roh HK, Dahl ML, Tybring G, CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6(6):547-51
   PubMedGoogle Scholar
• Kaneko A, Lum JK, Yaviong L, High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics 1999;9(5):581-90
   PubMedGoogle Scholar
• Ferguson RJ, De Morais SM, Benhamou S, A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998;284(1):356-61
   PubMed Web of Science ®Google Scholar
• Ibeanu GC, Blaisdell J, Ferguson RJ, A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 1999;290(2):635-40
   PubMed Web of Science ®Google Scholar
• Blaisdell J, Mohrenweiser H, Jackson J, Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 2002;12(9):703-11
   PubMedGoogle Scholar
• Timm R, Kaiser R, Lotsch J, Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J 2005;5(6):365-73
   PubMed Web of Science ®Google Scholar
• Ruiter R, Bijl MJ, van Schaik RH, CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 2010;11(10):1367-75
   PubMed Web of Science ®Google Scholar
• Luo HR, Poland RE, Lin KM, Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther 2006;80(1):33-40
   PubMed Web of Science ®Google Scholar
• Xiao ZS, Goldstein JA, Xie HG, Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997;281(1):604-9
   PubMed Web of Science ®Google Scholar
• Bernard S, Neville KA, Nguyen AT, Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 2006;11(2):126-35
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116(3):496-526
   PubMed Web of Science ®Google Scholar
• Schroth W, Goetz MP, Hamann U, Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302(13):1429-36
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Simon SD, Pearce RE, The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83(2):234-42
   PubMed Web of Science ®Google Scholar
• Bosch TM, Meijerman I, Beijnen JH, Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006;45(3):253-85
   PubMed Web of Science ®Google Scholar
• Higgins MJ, Stearns V. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep 2010;12(1):7-15
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5(1):6-13
   PubMed Web of Science ®Google Scholar
• Man M, Farmen M, Dumaual C, Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 2010;50(8):929-40
   PubMed Web of Science ®Google Scholar
• Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69(2):223-40
   PubMed Web of Science ®Google Scholar
• Dai D, Tang J, Rose R, Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001;299(3):825-31
   PubMed Web of Science ®Google Scholar
• Murayama N, Nakamura T, Saeki M, CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation. Drug Metab Pharmacokinet 2002;17(2):150-6
   PubMedGoogle Scholar
• Eiselt R, Domanski TL, Zibat A, Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001;11(5):447-58
   PubMedGoogle Scholar
• Nakajima Y, Yoshitani T, Fukushima-Uesaka H, Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin Pharmacol Ther 2006;80(2):179-91
   PubMed Web of Science ®Google Scholar
• Tran A, Jullien V, Alexandre J, Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79(6):570-80
   PubMed Web of Science ®Google Scholar
• Wegman P, Elingarami S, Carstensen J, Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007;9(1):R7
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27(4):383-91
   PubMed Web of Science ®Google Scholar
• Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 2006;45(1):13-31
   PubMed Web of Science ®Google Scholar
• Takahashi N, Miura M, Scott SA, Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 2010;55(11):731-7
   PubMed Web of Science ®Google Scholar
• Dennison JB, Jones DR, Renbarger JL, Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 2007;321(2):553-63
   PubMed Web of Science ®Google Scholar
• Yamaori S, Yamazaki H, Iwano S, Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. Xenobiotica 2005;35(1):69-83
   PubMed Web of Science ®Google Scholar
• Fukushima-Uesaka H, Saito Y, Watanabe H, Haplotypes of CYP3A4 and their close linkages with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004;23:100
   PubMedGoogle Scholar
• Yang P, Ebbert JO, Sun Z, Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 2006;24(11):1761-9
   PubMed Web of Science ®Google Scholar
• Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88
   PubMed Web of Science ®Google Scholar
• Edvardsen H, Brunsvig PF, Solvang H, SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. Pharmacogenomics J 2010;10(6):513-23
   PubMed Web of Science ®Google Scholar
• Lecomte T, Landi B, Beaune P, Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006;12(10):3050-6
   PubMed Web of Science ®Google Scholar
• Wang B, Huang G, Wang D, Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol 2010;53(3):508-18
   PubMed Web of Science ®Google Scholar
• Li D, Dandara C, Parker MI. The 341C/T polymorphism in the GSTP1 gene is associated with increased risk of oesophageal cancer. BMC Genet 2010;11(47):47
   PubMedGoogle Scholar
• Cho HJ, Eom HS, Kim HJ, Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet Cytogenet 2010;198(1):40-6
   PubMed Web of Science ®Google Scholar
• Stoehlmacher J, Park DJ, Zhang W, A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91(2):344-54
   PubMed Web of Science ®Google Scholar
• Oliveira AL, Rodrigues FF, Santos RE, GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genet Mol Res 2010;9(2):1045-53
   PubMed Web of Science ®Google Scholar
• Booton R, Ward T, Heighway J, Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol 2006;1(7):679-83
   PubMed Web of Science ®Google Scholar
• Mir O, Alexandre J, Tran A, Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 2009;20(4):736-40
   PubMed Web of Science ®Google Scholar
• Kim SD, Lee JH, Hur EH, Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;5:5
   Google Scholar
• Zwaveling J, Press RR, Bredius RG, Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit 2008;30(4):504-10
   PubMed Web of Science ®Google Scholar
• Ekhart C, Doodeman VD, Rodenhuis S, Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol 2009;67(1):50-60
   PubMed Web of Science ®Google Scholar
• Guillemette C, Levesque E, Harvey M, UGT genomic diversity: beyond gene duplication. Drug Metab Rev 2010;42(1):24-44
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Nakajima M, Ohashi N, Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug Metab Dispos 2003;31(5):589-95
   PubMed Web of Science ®Google Scholar
• Ando Y, Fujita K, Sasaki Y, UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Curr Opin Mol Ther 2007;9(3):258-62
   PubMed Web of Science ®Google Scholar
• Glimelius B, Garmo H, Berglund A, Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 2010;23:23
   Google Scholar
• Stewart CF, Panetta JC, O'Shaughnessy MA, UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007;25(18):2594-600
   PubMed Web of Science ®Google Scholar
• Kishi S, Yang W, Boureau B, Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004;103(1):67-72
   PubMed Web of Science ®Google Scholar
• Akaba K, Kimura T, Sasaki A, Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int 1998;46(1):21-6
   PubMedGoogle Scholar
• Minami H, Sai K, Saeki M, Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007;17(7):497-504
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Soda H, Oka M, Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. J Thorac Oncol 2011;6(1):121-7
   PubMed Web of Science ®Google Scholar
• Morsman JM, Sludden J, Ameyaw MM, Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. Br J Clin Pharmacol 2000;50(3):269-72
   PubMed Web of Science ®Google Scholar
• Maring JG, Groen HJ, Wachters FM, Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 2005;5(4):226-43
   PubMed Web of Science ®Google Scholar
• Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000;61(3):199-203
   PubMed Web of Science ®Google Scholar
• Sai K, Saito Y, Maekawa K, Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol 2010;66(1):95-105
   PubMed Web of Science ®Google Scholar
• Cha PC, Mushiroda T, Zembutsu H, Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet 2009;54(10):572-80
   PubMed Web of Science ®Google Scholar
• Innocenti F, Kroetz DL, Schuetz E, Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009;27(16):2604-14
   PubMed Web of Science ®Google Scholar
• Reigner B, Watanabe T, Schuller J, Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 2003;52(3):193-201
   PubMed Web of Science ®Google Scholar
• Lewis LD, Miller AA, Rosner GL, A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 2007;13(11):3302-11
   PubMed Web of Science ®Google Scholar
• Ranson M, Wilson RH, O'Sullivan JM, Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer. Int J Clin Pharmacol Ther 2010;48(11):708-17
   PubMed Web of Science ®Google Scholar
• Garte S, Gaspari L, Alexandrie AK, Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001;10(12):1239-48
   PubMed Web of Science ®Google Scholar
• Inoue K, Asao T, Shimada T. Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations. Xenobiotica 2000;30(3):285-95
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996;56(21):4965-9
   PubMed Web of Science ®Google Scholar
• Davaalkham J, Hayashida T, Tsuchiya K, Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population. Drug Metab Dispos 2009;37(10):1991-3
   PubMed Web of Science ®Google Scholar
• Guan S, Huang M, Li X, Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharm Res 2006;23(9):1983-90
   PubMed Web of Science ®Google Scholar
• Kim KA, Song WK, Park JY. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther 2009;86(5):511-18
   PubMed Web of Science ®Google Scholar
• Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005;77(5):341-52
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Gomez A, Karlgren M, Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet 2010;127(1):1-17
   PubMed Web of Science ®Google Scholar
• Scordo MG, Caputi AP, D'Arrigo C, Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50(2):195-200
   PubMed Web of Science ®Google Scholar
• Sata F, Sapone A, Elizondo G, CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000;67(1):48-56
   PubMed Web of Science ®Google Scholar
• Zeigler-Johnson CM, Walker AH, Mancke B, Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002;54(1):13-21
   PubMed Web of Science ®Google Scholar
• Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6(9):733-43
   PubMed Web of Science ®Google Scholar
• Nelson HH, Wiencke JK, Christiani DC, Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995;16(5):1243-5
   PubMed Web of Science ®Google Scholar
• Zhong SL, Zhou SF, Chen X, Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese. Eur J Pharm Sci 2006;28(1-2):77-85
   PubMed Web of Science ®Google Scholar
• Lampe JW, Bigler J, Horner NK, UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999;9(3):341-9
   PubMedGoogle Scholar